{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T10:30:18Z","timestamp":1795170618862,"version":"4.10.3"},"reference-count":82,"publisher":"American Society of Hematology","issue":"27","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Preclinical studies of BCR-ABL mutation sensitivity to nilotinib or dasatinib suggested that the majority would be sensitive. Correspondingly, the initial clinical trials demonstrated similar response rates for CML patients after imatinib failure, irrespective of the mutation status. However, on closer examination, clinical evidence now indicates that some mutations are less sensitive to nilotinib (Y253H, E255K\/V, and F359V\/C) or dasatinib (F317L and V299L). T315I is insensitive to both. Novel mutations (F317I\/V\/C and T315A) are less sensitive\/insensitive to dasatinib. We refer to these collectively as second-generation inhibitor (SGI) clinically relevant mutations. By in vitro analysis, other mutations confer a degree of insensitivity; however, clinical evidence is currently insufficient to define them as SGI clinically relevant. Here we examine the mutations that are clearly SGI clinically relevant, those with minimal impact on response, and those for which more data are needed. In our series of patients with mutations at imatinib cessation and\/or at nilotinib or dasatinib commencement, 43% had SGI clinically relevant mutations, including 14% with T315I. The frequency of SGI clinically relevant mutations was dependent on the disease phase at imatinib failure. The clinical data suggest that a mutation will often be detectable after imatinib failure for which there is compelling clinical evidence that one SGI should be preferred.<\/jats:p>","DOI":"10.1182\/blood-2009-08-215939","type":"journal-article","created":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T00:46:09Z","timestamp":1256949969000},"page":"5426-5435","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":140,"title":["Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?"],"prefix":"10.1182","volume":"114","author":[{"given":"Susan","family":"Branford","sequence":"first","affiliation":[{"name":"Centre for Cancer Biology, Departments of Molecular Pathology and Haematology, SA Pathology, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, Departments of Molecular Pathology and Haematology, SA Pathology, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, Departments of Molecular Pathology and Haematology, SA Pathology, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5531","key":"2019111723241028700_B1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"2","key":"2019111723241028700_B2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"11","key":"2019111723241028700_B3","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"issue":"9305","key":"2019111723241028700_B4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"2019111723241028700_B5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"18","key":"2019111723241028700_B6","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","article-title":"ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111723241028700_B7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP).","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"2019111723241028700_B8","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"24","key":"2019111723241028700_B9","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111723241028700_B10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111723241028700_B11","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"issue":"29","key":"2019111723241028700_B12","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111723241028700_B13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2019111723241028700_B14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2019111723241028700_B15","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111723241028700_B16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"issue":"5486","key":"2019111723241028700_B17","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"issue":"15","key":"2019111723241028700_B18","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"2019111723241028700_B19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389557043487321","article-title":"Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.","volume":"4","author":"Cowan-Jacob","year":"2004","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"2019111723241028700_B20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL.","volume":"11","author":"Nardi","year":"2004","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2019111723241028700_B21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL.","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"issue":"4","key":"2019111723241028700_B22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.leu.2404151","article-title":"The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.","volume":"20","author":"Miething","year":"2006","journal-title":"Leukemia"},{"issue":"24","key":"2019111723241028700_B23","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111723241028700_B24","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111723241028700_B25","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111723241028700_B26","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111723241028700_B27","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2019111723241028700_B28","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"19","key":"2019111723241028700_B29","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111723241028700_B30","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111723241028700_B31","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial.","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5682","key":"2019111723241028700_B32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"11","key":"2019111723241028700_B33","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"2","key":"2019111723241028700_B34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"2019111723241028700_B35","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2019111723241028700_B36","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111723241028700_B37","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations.","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111723241028700_B38","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111723241028700_B39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111723241028700_B40","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111723241028700_B41","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"issue":"16","key":"2019111723241028700_B42","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1073\/pnas.162140299","article-title":"Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.","volume":"99","author":"Roumiantsev","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111723241028700_B43","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","article-title":"Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).","volume":"108","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111723241028700_B44","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111723241028700_B45","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2019111723241028700_B46","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2019111723241028700_B47","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111723241028700_B48","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111723241028700_B49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"2019111723241028700_B50","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"12","key":"2019111723241028700_B51","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2019111723241028700_B52","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2019111723241028700_B53","first-page":"258","article-title":"Response to nilotinib is similar in imatinib-resistant chronic myeloid leukemia patients in accelerated phase (CML-AP) with and without BCR-ABL mutations except E255K\/V, Y253H, and F359C\/V [abstract].","volume":"94","author":"Martinelli","year":"2009","journal-title":"Haematologica"},{"issue":"10","key":"2019111723241028700_B54","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2008.97","article-title":"Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR).","volume":"22","author":"Preuner","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111723241028700_B55","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2404635","article-title":"High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations.","volume":"21","author":"Vivante","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2019111723241028700_B56","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.","volume":"19","author":"Gruber","year":"2005","journal-title":"Leukemia"},{"issue":"11","key":"2019111723241028700_B57","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0145-2126(03)00066-3","article-title":"Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.","volume":"27","author":"Liu","year":"2003","journal-title":"Leuk Res"},{"issue":"6","key":"2019111723241028700_B58","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.onc.1210698","article-title":"Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.","volume":"27","author":"Nardi","year":"2008","journal-title":"Oncogene"},{"issue":"6","key":"2019111723241028700_B59","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111723241028700_B60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/leu.2008.183","article-title":"Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.","volume":"23","author":"Oehler","year":"2008","journal-title":"Leukemia"},{"issue":"51","key":"2019111723241028700_B61","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"2019111723241028700_B62","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2019111723241028700_B63","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia.","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"27","key":"2019111723241028700_B64","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays.","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"1","key":"2019111723241028700_B65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2019111723241028700_B66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03195613","article-title":"Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.","volume":"49","author":"Baranska","year":"2008","journal-title":"J Appl Genet"},{"issue":"9","key":"2019111723241028700_B67","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"2019111723241028700_B68","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate.","volume-title":"Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine","author":"Branford","year":"2006"},{"issue":"5","key":"2019111723241028700_B69","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","article-title":"Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.","volume":"99","author":"Hofmann","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2019111723241028700_B70","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","article-title":"Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.","volume":"85","author":"Sill","year":"1995","journal-title":"Blood"},{"key":"2019111723241028700_B71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.1995.tb05358.x","article-title":"Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia.","volume":"91","author":"Serra","year":"1995","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111723241028700_B72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0301-472X(02)01075-5","article-title":"Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients.","volume":"31","author":"Hernandez-Boluda","year":"2003","journal-title":"Exp Hematol"},{"key":"2019111723241028700_B73","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gad.1673908","article-title":"Failure of CDKN2A\/B (INK4A\/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.","volume":"22","author":"Mullighan","year":"2008","journal-title":"Genes Dev"},{"issue":"10","key":"2019111723241028700_B74","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1182\/blood-2008-02-142190","article-title":"The biologic properties of leukemias arising from BCR\/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111723241028700_B75","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis.","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111723241028700_B76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"issue":"45","key":"2019111723241028700_B77","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111723241028700_B78","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111723241028700_B79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428199709051771","article-title":"p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia.","volume":"26","author":"Guinn","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111723241028700_B80","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V83.12.3449.3449","article-title":"Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia.","volume":"83","author":"Wada","year":"1994","journal-title":"Blood"},{"issue":"8","key":"2019111723241028700_B81","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression.","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"2019111723241028700_B82","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The biology of CML blast crisis.","volume":"2007","author":"Radich","year":"2007","journal-title":"Hematology"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/27\/5426\/1321892\/zh805209005426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/27\/5426\/1321892\/zh805209005426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T04:24:39Z","timestamp":1574051079000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/114\/27\/5426\/26560\/Selecting-optimal-secondline-tyrosine-kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,24]]},"references-count":82,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2009,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-08-215939","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,24]]}}}